Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells

Prostate

Volumn 53, Issue 3, 2002, Pages 211-217

  Tyagi, Alpana ^a   Bhatia, Neehar ^a   Condon, Mark S ^b,c   Bosland, Maarten C ^c   Agarwal, Chapla ^a   Agarwal, Rajesh ^a,d  

^a UNIVERSITY OF COLORADO   (United States)

^b SUNY Dutchess Community College   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

Apoptosis; Cell cycle; Flavonoid antioxidant; Prostate cancer; Silibinin; Silymarin

Indexed keywords

CELL DNA; SILIBININ; SILYMARIN;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL DEATH; CONTROLLED STUDY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; ANNEXIN A5; APOPTOSIS; BROMODEOXYURIDINE; CELL CYCLE; CELL DIVISION; COLORING AGENTS; DNA DAMAGE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; MALE; PROPIDIUM; PROSTATIC NEOPLASMS; RATS; SILYMARIN; TRYPAN BLUE; TUMOR CELLS, CULTURED;

EID: 0036843213     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10146     Document Type: Article

References (28)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J Clin 2001;51:15-36.
2. Crawford ED, Nabors W. Hormone therapy of advanced prostate cancer: Where we stand today. Oncology (Huntingt) 1991;5:21-30.
3. Coffey DS. Prostate cancer. An overview of an increasing dilemma. Cancer 1993;71(Suppl):880-886.
4. Agarwal R, Mukhtar H. Chemoprevention of photocarcinogenesis. Photochem Photobiol 1996;63:440-444.
5. Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997;278:1073-1077.
6. Lippman SM, Lee JJ, Sabichi AL. Cancer chemoprevention: Progress and promise. J Natl Cancer Inst 1998;90:1514-1528.
7. Kelloff GJ. Perspectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000;78:199-334.
8. Hill MJ. Nutrition and human cancer. Ann Ny Acad Sci. 1997; 833:68-78.
9. Wargovich MJ. Nutrition and cancer: The herbal revolution. Curr Opin Clin Nutr Metab Care 1999;2:421-424.
10. Dragsted LO. Natural antioxidants in chemoprevention. Arch Toxicol Suppl 1998;20:209-226.
11. Wagner H, Diesel P, Seitz M. The chemistry and analysis of silymarin from Silybum marianum Gaertn. Arzneimittelforschung 1974;24:466-471.
12. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 1998;93:139-143.
13. Comoglio A, Leonarduzzi G, Carini R, Busolin D, Basaga H, Albano E, Tomasi A, Poli G, Morazzoni P, Magistretti MJ. Studies on the antioxidant and free radical scavenging properties of IdB1016 a new flavanolignan complex. Free Radic Res Commun 1990;11:109-115.
14. Vogel G, Trost W, Braatz R, Odenthal KP, Brusewitz G, Antweiler H, Seeger R. Pharmacodynamics, site and mechanism of action of silymarin, the antihepatoxic principle from Silybum mar. (L) Gaertn. 1. Acute toxicology or tolerance, general and specific (liver-) pharmacology. Arzneimittelforschung 1975;25: 82-89.
15. Agarwal R, Katiyar SK, Lundgren DW, Mukhtar H. Inhibitory effect of silymarin, an anti-hepatotoxic flavonoid, on 12-0-tetradecanoylphorbol-13-acetate-induced epidermal ornithine decarboxylase activity and mRNA in SENCAR mice. Carcinogenesis 1994;15:1099-1103.
16. Katiyar SK, Korman NJ, Mukhtar H, Agarwal R. Protective effects of silymarin against photocarcinogenesis in mouse skin model. J Natl Cancer Inst 1997;8:556-566.
17. Zi X, Feyes DK, Agarwal R. Anticarcinogenic effect of a flavonoid antioxidant silymarin in human breast cancer cells MDA-MB 468: Induction of G1 arrest through an increase in Cip1/p21 concomitant with a decrease in kinase activity of cyclin dependent kinases and associated cyclins. Clin Cancer Res 1998;4:1055-1064.
18. Zi X, Grasso AW, Kung HJ, Agarwal R. A flavonoid antioxidant, silymarin, inhibits activation of erbB1 signaling and induces cyclin-dependent kinase inhibitors, G1 arrest, and anticarcinogenic effects in human prostate carcinoma DU145 cells. Cancer Res 1998;58:1920-1929.
19. Lahiri-Chatterjee M, Katiyar SK, Mohan RR, Agarwal R. A flavonoid antioxidant, silymarin, affords exceptionally high protection against tumor promotion in SENCAR mouse skin tumorigenesis model. Cancer Res 1999;59:622-632.
20. Zi X, Agarwal R. Silibinin decreases prostate-specific antigen with cell growth inhibition via G1 arrest, leading to differentiation of prostate carcinoma cells: Implications for prostate cancer intervention. Proc Natl Acad Sci USA 1999;96:7490-7495.
21. Bosland MC. Animal models for the study of prostate carcinogenesis. J Cell Biochem Suppl 1992;16H:89-98.
22. Bosland MC, Chung LWK, Chung NM, Greenberg NM, Ho S-M, Isaacs JT, Lane K, Peehl EM, Thompson JC, van Steenbrugge GJ, van Weerden WM. Recent advances in the development of animal and cell culture models for prostate cancer research: A minireview. Urol Oncol 1997;2:99-128.
23. Green JE, Greenberg NM, Ashendel CL, Barrett JC, Boone C, Getzenberg RH, Henkin J, Matusik R, Janus TJ, Scher HI. Workgroup 3: Transgenic and reconstitution models of prostate cancer. Prostate 1998;36:59-63.
24. Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA. Workgroup I: Rodents models of prostate cancer. Prostate 1998;36:49-55.
25. Condon MS, Kaplan LA, Crivello JF, Horton L, Bosland MC. Multiple pathways of prostate carcinogenesis analyzed by using cultured cells isolated from rats treated with N-methyl-N-nitrosourea and testosterone. Mol Carcinog 1999;25:179-186.
26. Bosland MC, Prinsen MK. Induction of dorsolateral prostate adenocarcinomas and other accessory sex gland lesions in male Wistar rats by a single administration of N-methyl-N-nitrosourea, 7,12-dimethylbenz(a)anthracene, and 3,2′-dimethyl-4- aminobiphenyl after sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res 1990;50:691-699.
27. Abate-Shen C, Shen MM. Molecular genetics of prostate cancer. Genes Dev 2000;14:2410-2434.
28. Agarwal R. Cell signaling and regulators of cell cycle as molecular targets for prostate cancer prevention by dietary agents. Biochem Pharmacol 2000;60:1051-1059.